155 related articles for article (PubMed ID: 31053856)
21. Variability of three activated clotting time point-of-care systems in cardiac surgery: reinforcing available evidence.
Solís Clavijo D; Cotano AO; Peña NA; Caballero Gálvez S; Arellano Núñez F; Carballo Caro JM; Muñoz-Cacho P; Tocón Alé C
Perfusion; 2022 Oct; 37(7):711-714. PubMed ID: 34109886
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evaluation of heparin concentration and activated clotting time monitoring (HEPCON HMS) system].
Sakurada T; Kikuchi Y; Koushima R; Nakashima S; Hachiro Y; Kagaya H
Nihon Kyobu Geka Gakkai Zasshi; 1997 Jun; 45(6):836-40. PubMed ID: 9217380
[TBL] [Abstract][Full Text] [Related]
23. Point-of-Care Measurement of Kaolin Activated Clotting Time during Cardiopulmonary Bypass: A Single Sample Comparison between ACT Plus and i-STAT.
Vranken NPA; Theelen AJAJ; Orbons T; Barenbrug PJC; Weerwind PW
J Extra Corpor Technol; 2021 Mar; 53(1):57-61. PubMed ID: 33814607
[TBL] [Abstract][Full Text] [Related]
24. Activated Clotting Time (ACT) for Monitoring of Low-Dose Heparin: Performance Characteristics in Healthy Adults and Critically Ill Patients.
Wehner JE; Boehne M; David S; Brand K; Tiede A; Bikker R
Clin Appl Thromb Hemost; 2020; 26():1076029620975494. PubMed ID: 33350327
[TBL] [Abstract][Full Text] [Related]
25. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery.
Niles SD; Sutton RG; Ploessl J; Pennell B
J Extra Corpor Technol; 1995 Dec; 27(4):197-200. PubMed ID: 10172651
[TBL] [Abstract][Full Text] [Related]
26. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
[TBL] [Abstract][Full Text] [Related]
27. Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation.
Figueroa Villalba CA; Brogan TV; McMullan DM; Yalon L; Jordan DI; Chandler WL
Crit Care Med; 2020 Dec; 48(12):e1179-e1184. PubMed ID: 33009103
[TBL] [Abstract][Full Text] [Related]
28. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
29. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
Hellstern P; Bach J; Simon M; Saggau W
J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
[TBL] [Abstract][Full Text] [Related]
30. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
[TBL] [Abstract][Full Text] [Related]
31. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
[TBL] [Abstract][Full Text] [Related]
32. Alternative methods for anticoagulation monitoring in pediatric patients with applicability to a patient with severe hemophilia A and circulating inhibitor.
McNamara JL; Lombardi JP; Ferguson R; Manning PB; Gruppo RA
J Extra Corpor Technol; 2001 Dec; 33(4):239-42. PubMed ID: 11806436
[TBL] [Abstract][Full Text] [Related]
33. The Hemochron Response RxDx heparin and protamine dosing system.
Jaryno SA; Zucker ML; LaDuca FM
J Extra Corpor Technol; 2004 Sep; 36(3):258-62. PubMed ID: 15559745
[TBL] [Abstract][Full Text] [Related]
34. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass.
Gruenwald C; de Souza V; Chan AK; Andrew M
Perfusion; 2000 Jun; 15(3):203-9. PubMed ID: 10866421
[TBL] [Abstract][Full Text] [Related]
35. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass.
Welsby IJ; McDonnell E; El-Moalem H; Stafford-Smith M; Toffaletti JG
J Clin Monit Comput; 2002 Jul; 17(5):287-92. PubMed ID: 12546261
[TBL] [Abstract][Full Text] [Related]
36. Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400.
Colby CE; Sheehan A; Benitz W; Van Meurs K; Halamek LP; Moss RL
J Extra Corpor Technol; 2003 Mar; 35(1):35-8. PubMed ID: 12680494
[TBL] [Abstract][Full Text] [Related]
37. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
38. The value of heparin concentration monitoring in off-pump coronary bypass surgery.
Baykut D; Weichelt K; Wehrle J; Zerkowski HR; Bernet F
Eur J Med Res; 2003 Apr; 8(4):161-4. PubMed ID: 12765862
[TBL] [Abstract][Full Text] [Related]
39. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques.
Mabry CD; Thompson BW; Read RC; Campbell GS
Surgery; 1981 Nov; 90(5):889-95. PubMed ID: 7302842
[TBL] [Abstract][Full Text] [Related]
40. A new method of measuring heparin levels in whole blood by protamine titration using a heparin-responsive electrochemical sensor.
Wahr JA; Yun JH; Yang VC; Lee LM; Fu B; Meyerhoff ME
J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):447-50. PubMed ID: 8776635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
